clinical trial · NCT02254967
A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population
Astellas Pharma Europe Ltd.·phase4·completed·n = 364
Clostridium DifficileFidaxomicinVancomycin
brief summary
The main objective of the study is to evaluate whether the extended duration fidaxomicin therapy is superior to the standard vancomycin therapy in sustained clinical cure of CDI at 30 days after end of treatment (Day 40 or Day 55).
started
Nov 6, 2014
primary completion
Mar 27, 2016
completion
May 5, 2016
last updated
Oct 31, 2024
official title
A Phase IIIB/IV Randomized, Controlled, Open-label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium Difficile Infection in an Older Population
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol